[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559331":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":38,"centralContacts":43,"locations":52,"responsibleParty":71,"collaborators":74,"id":77,"slug":17,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":17,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":17,"enrollmentInfo":84,"targetDuration":17,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":55,"whyStopped":17,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"The Third People's Hospital of Chengdu","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Platelet elevation","Proportion of patients achieving perioperative platelet count goals (≥80×10\\^9\u002F L for major surgery and ≥50×10\\^9\u002F L for minor surgery) without emergency treatment","up to 14 days",[14],{"measure":15,"description":16,"timeFrame":12},"Secondary Outcome","The median time to reach the platelet count target;",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","It was planned to include 55 patients with immune thrombocytopenia with preoperative platelet ≤75×10\\^9\u002FL. After signing the informed consent letter, the patients will enter the screening period (up to 7 days), and after passing the screening, they will receive oral hexapopal treatment, the specific medication regimen is: 7.5mg, once a day, taken orally on an empty stomach before going to bed, for a maximum of 14 days, and stop the drug when PLT≥100×10\\^9\u002FL. During the oral administration of hexapopal, the administration was suspended when PLT≥200×10\\^9\u002FL, and continued when the blood image was monitored weekly until PLT \\\u003C 100×10\\^9\u002FL. During the treatment period, blood routine was monitored every 7 days, and when PLT≤30×10\\^9\u002FL or ≥300×10\\^9\u002FL, blood routine was monitored every 3 days. Patients will have an end-of-treatment visit within 7 days of stopping treatment, followed by a 30-day safe follow-up period.",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"Experimental: Hetrombopag arm","EXPERIMENTAL","Takes Hetrombopag 7.5 mg\u002Fday at bedtime for at most 14 days.",[31],"Drug: Hetrombopag",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":17},"DRUG","Hetrombopag","Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\\^9\u002FL, and take blood routine examination weekly, drug administration was resumed when PLT \\\u003C 100 ×10\\^9\u002FL. When PLT ≤30× 10\\^9\u002FL or ≥300 ×10\\^9\u002FL, take blood routine examination every 3 days.",[27],[39],{"name":40,"affiliation":41,"role":42},"JING TAN, MD","成都市第三人民医院","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":17,"email":48},"Ying Li, PhD","CONTACT","+86 028 61318717","79468064@qq.com",{"name":50,"role":46,"phone":47,"phoneExt":17,"email":51},"Zuofeng Liu, Master","641206088@qq.com",[53],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Chengdu Third People's Hospital","RECRUITING","Chengdu","Sichuan","610000","China","CN",{"type":62,"coordinates":63},"Point",[64,65],104.06667,30.66667,{"lat":65,"lon":64},[68],{"name":69,"role":46,"phone":47,"phoneExt":17,"email":70},"Jing Tan, PhD","tanjing@nsmc.edu.cn",{"type":42,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Ying Li","Principal Investigator",[75],{"name":76,"class":6},"Affiliated Hospital of North Sichuan Medical College","100559331",false,"NCT06562738","Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia","Inclusion Criteria:\n\n1. Age ≥18 years old; diagnosis of immune thrombocytopenia.\n2. Platelets ≤75×10\\^9\u002FL before scheduled elective surgery.\n\nExclusion Criteria:\n\n1. History of allergy to Thrombopoietin Receptor Agonists (TPO-RA) drugs;\n2. Severe bleeding symptoms, such as gastrointestinal bleeding, bleeding of important organs, and intracranial bleeding;\n3. Thrombotic diseases, such as pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation (DIC);\n4. Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody;\n5. New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure;\n6. History of angina pectoris, myocardial infarction or cerebral infarction within 6 months before the screening period;\n7. Have an active infection that is difficult to control;\n8. Pregnant or lactating women;\n9. Other conditions determined by the investigator to be unsuitable for inclusion in the study","ALL","18 Years",{"count":85,"type":86},55,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery",[92],"Thrombocytopenia",[35,92,94],"Preoperative","2024-08-17",{"date":97,"type":98},"2024-08-20","ACTUAL",{"date":100,"type":98},"2024-06-01",{"date":102,"type":86},"2025-03-31",{"name":5,"class":6},1]